In the present study, beauvericin was found to ameliorate inflammatory bowel disease in mice and its mechanisms were related to inhibiting activated T lymphocytes via downregulation of PI3K/Akt signaling. This evidence concerns the gene AKT1 and inflammatory bowel disease.